Visgenx develops therapeutics to protect against the loss of sight from retinal disorders. Its programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders. Its programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.
